The 2016 revision of the World Health Organization classification of lymphoid neoplasms
SH Swerdlow, E Campo, SA Pileri… - Blood, The Journal …, 2016 - ashpublications.org
A revision of the nearly 8-year-old World Health Organization classification of the lymphoid
neoplasms and the accompanying monograph is being published. It reflects a consensus …
neoplasms and the accompanying monograph is being published. It reflects a consensus …
Management of adverse events associated with idelalisib treatment: expert panel opinion
SE Coutré, JC Barrientos, JR Brown… - Leukemia & …, 2015 - Taylor & Francis
Idelalisib is a first-in-class selective, oral, phosphatidylinositol 3-kinase delta (PI3Kδ)
inhibitor approved for the treatment of several types of blood cancer. Idelalisib has …
inhibitor approved for the treatment of several types of blood cancer. Idelalisib has …
Overview of lymphoma diagnosis and management
MJ Matasar, AD Zelenetz - Radiologic Clinics of North America, 2008 - Elsevier
The malignant lymphomas, including both Hodgkin lymphoma (HL) and non-Hodgkin
lymphoma (NHL), represent a diverse group of diseases that arise from a clonal proliferation …
lymphoma (NHL), represent a diverse group of diseases that arise from a clonal proliferation …
The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee
Since the publication of the Revised European-American Classification of Lymphoid
Neoplasms in 1994, subsequent updates of the classification of lymphoid neoplasms have …
Neoplasms in 1994, subsequent updates of the classification of lymphoid neoplasms have …
[HTML][HTML] Idelalisib and rituximab in relapsed chronic lymphocytic leukemia
RR Furman, JP Sharman, SE Coutre… - … England Journal of …, 2014 - Mass Medical Soc
Background Patients with relapsed chronic lymphocytic leukemia (CLL) who have clinically
significant coexisting medical conditions are less able to undergo standard chemotherapy …
significant coexisting medical conditions are less able to undergo standard chemotherapy …
[HTML][HTML] Genetics and pathogenesis of diffuse large B-cell lymphoma
R Schmitz, GW Wright, DW Huang… - New England journal …, 2018 - Mass Medical Soc
Background Diffuse large B-cell lymphomas (DLBCLs) are phenotypically and genetically
heterogeneous. Gene-expression profiling has identified subgroups of DLBCL (activated B …
heterogeneous. Gene-expression profiling has identified subgroups of DLBCL (activated B …
Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and …
KR Carson, AM Evens, EA Richey… - Blood, The Journal …, 2009 - ashpublications.org
Rituximab improves outcomes for persons with lymphoproliferative disorders and is
increasingly used to treat immune-mediated illnesses. Recent reports describe 2 patients …
increasingly used to treat immune-mediated illnesses. Recent reports describe 2 patients …
An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era
Z Zhou, LH Sehn, AW Rademaker… - Blood, The Journal …, 2014 - ashpublications.org
Abstract The International Prognostic Index (IPI) has been the basis for determining
prognosis in patients with aggressive non-Hodgkin lymphoma (NHL) for the past 20 years …
prognosis in patients with aggressive non-Hodgkin lymphoma (NHL) for the past 20 years …
[HTML][HTML] Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an …
C Casulo, M Byrtek, KL Dawson, X Zhou… - Journal of Clinical …, 2015 - ncbi.nlm.nih.gov
Purpose Twenty percent of patients with follicular lymphoma (FL) experience progression of
disease (POD) within 2 years of initial chemoimmunotherapy. We analyzed data from the …
disease (POD) within 2 years of initial chemoimmunotherapy. We analyzed data from the …
Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas
MS Kaminski, AD Zelenetz, OW Press… - Journal of clinical …, 2001 - ascopubs.org
PURPOSE: To evaluate the efficacy and safety of tositumomab and iodine I 131
tositumomab (Bexxar; Corixa Corp, Seattle, WA, and GlaxoSmithKline, Philadelphia, PA) in …
tositumomab (Bexxar; Corixa Corp, Seattle, WA, and GlaxoSmithKline, Philadelphia, PA) in …